Yumanity Therapeutics

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Founded in December 2014 by award winning protein folding expert, Susan Lindquist, Ph.D., and renowned biotech industry leader, Tony Coles, M.D., Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). The company’s proprietary platforms have already identified one potential new target for treating Parkinson’s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer’s disease and ALS. Diseases affecting the brain and central nervous system represent one of the largest global healthcare challenges and greatest medical needs due to the devastating personal and economic consequences for patients, caregivers and society. Despite the fact that an estimated 50 million people worldwide suffer from them, there are no approved disease-modifying therapies or cures. Leveraging its three integrated discovery platforms, Yumanity’s new approach to drug discovery and development concentrates on the cell’s characteristics, or phenotype, and the disease pathologies caused by protein misfolding.
Show more
TypeSubsidiary
Parent CompanyProteostasis Therapeutics
HQCambridge, US
Founded2014
Websiteyumanity.com
Cybersecurity ratingAMore
Yumanity Therapeutics was founded in 2014 and is headquartered in Cambridge, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Yumanity Therapeutics

Richard Peters

Richard Peters

Chief Executive Officer
Tony Coles

Tony Coles

Executive Chairman and Co-Founding Investor, Director
Paulash Mohsen

Paulash Mohsen

Chief Business Officer
Patricia Allen

Patricia Allen

Director
Richard A. Heyman

Richard A. Heyman

Director
Brigitte Robertson

Brigitte Robertson

Chief Medical Officer
Show more

Yumanity Therapeutics Office Locations

Yumanity Therapeutics has offices in Cambridge and Boston
Cambridge, US (HQ)
790 Memorial Dr #2c
Boston, US
40 Guest St #4410
Show all (2)

Yumanity Therapeutics Financials and Metrics

Summary Metrics

In total, Yumanity Therapeutics had raised $51 m. Yumanity Therapeutics is a subsidiary of Proteostasis Therapeutics

Yumanity Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Yumanity Therapeutics Online and Social Media Presence

Embed Graph

Yumanity Therapeutics News and Updates

Yumanity backs onto Wall Street via Proteostasis merger

On the heels of a Big Pharma deal worth up to $500 million, Yumanity Therapeutics is merging its way onto Wall Street. The neuro-focused biotech is joining up with Proteostasis, which once planned to move a cystic fibrosis drug into the clinic this year but is now looking for someone to buy its pipe…

Yumanity Therapeutics Blogs

Yumanity Therapeutics Frequently Asked Questions

  • When was Yumanity Therapeutics founded?

    Yumanity Therapeutics was founded in 2014.

  • Who are Yumanity Therapeutics key executives?

    Yumanity Therapeutics's key executives are Richard Peters, Tony Coles and Paulash Mohsen.

  • How many employees does Yumanity Therapeutics have?

    Yumanity Therapeutics has 41 employees.

  • Who are Yumanity Therapeutics competitors?

    Competitors of Yumanity Therapeutics include Medisun Precision Medicine, Fulcrum Therapeutics and Immage Biotherapeutics.

  • Where is Yumanity Therapeutics headquarters?

    Yumanity Therapeutics headquarters is located at 790 Memorial Dr #2c, Cambridge.

  • Where are Yumanity Therapeutics offices?

    Yumanity Therapeutics has offices in Cambridge and Boston.

  • How many offices does Yumanity Therapeutics have?

    Yumanity Therapeutics has 2 offices.